^ abcdPradaxa Full Prescribing Information. Boehringer Ingelheim. October 2010.
^Hanley JP, J P (Nov 2004). “Warfarin reversal”. Journal of Clinical Pathology57 (11): 1132–9. doi:10.1136/jcp.2003.008904. PMC 1770479. PMID 15509671. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1770479/.
^Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; Meijers, JC; Buller, HR; Levi, M (2011-10-04). “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects”. Circulation124 (14): 1573–9. doi:10.1161/CIRCULATIONAHA.111.029017. PMID 21900088. http://circ.ahajournals.org/content/early/2011/09/06/CIRCULATIONAHA.111.029017.abstract2012年3月15日閲覧。.
^van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (Department of Drug Discovery Support, Boehringer Ingelheim Pharma) (Jun 2010). “Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity”. Thrombosis and Haemostasis103 (6): 1116–27. doi:10.1160/TH09-11-0758. PMID 20352166. http://www.ncbi.nlm.nih.gov/pubmed/203521662012年3月15日閲覧. "Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticoagulant activity."
^“プラザキサの中和剤idarucizumabに関する新データを公表-独ベーリンガー”. QLife Pro (2014年12月5日). 2015年2月27日閲覧。
^Gómez-Outes, A; Terleira-Fernández, AI; Calvo-Rojas, G; Suárez-Gea, ML; Vargas-Castrillón, E (2013). “Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups.”. Thrombosis2013: 640723. PMID 24455237.
^“FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves”. U.S. Food and Drug Administration (FDA). 2014年10月29日閲覧。
^Eikelboom, JW; Connolly, SJ; Brueckmann, M, et al. (September 2013). “Dabigatran versus Warfarin in Patients with Mechanical Heart Valves”. N Engl J Med369: 1206–1214. doi:10.1056/NEJMoa1300615. PMID 23991661.
^“Risk of Bleeding With Dabigatran in Atrial Fibrillation”. JAMA (2015年1月). 2015年2月28日閲覧。
^ML Blommel; and others (2011). “Dabigatran etexilate: A novel oral direct thrombin inhibitor”. Am J Health Syst Pharm68 (16): 1506–19. doi:10.2146/ajhp100348. PMID 21817082.
^Uchino K, Hernandez AV; Hernandez (2012). “Dabigatran associated with higher risk of acute coronary events - meta-analysis of noninferiority randomized controlled trials”. Arch. Intern. Med.Online first (5): 397–402. doi:10.1001/archinternmed.2011.1666. PMID 22231617. オリジナルの2012年4月23日時点によるアーカイブ。. https://web.archive.org/web/20120423115814/http://archinte.ama-assn.org/cgi/content/full/archinternmed.2011.1666.
^Chongnarungsin D; Ratanapo S; Srivali N; Ungprasert P; Suksaranjit P; Ahmed S; Cheungpasitporn W (2012). “In-Depth Review of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation”. Am. Med. J.3 (2): 100. doi:10.3844/amjsp.2012.100.103. http://thescipub.com/abstract/10.3844/amjsp.2012.100.103.
^Stangier J, Eriksson BI, Dahl OE; and others (May 2005). “Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement”. J Clin Pharmacol45 (5): 555–63. doi:10.1177/0091270005274550. PMID 15831779.
^"Pradaxa Summary of Product Characteristics" Archived 2011年3月22日, at the Wayback Machine.. European Medicines Agency.
^Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W; Nar; Priepke; Ries; Stassen; Wienen (April 2002). “Structure-based design of novel potent nonpeptide thrombin inhibitors”. J Med Chem45 (9): 1757–66. doi:10.1021/jm0109513. PMID 11960487. Lay summary.
^“Pradaxa EPAR”. European Medicines Agency. 2011年1月30日閲覧。[リンク切れ]
^"Summary Basis of Decision (SBD): Pradax" Health Canada. 2008-11-06.
^Kirkey, Sharon (2010年10月29日). “Approval of new drug heralds 'momentous' advance in stroke prevention”. Montreal Gazette(英語版). http://www.montrealgazette.com/health/Approval+drug+heralds+momentous+advance+stroke+prevention/3739714/story.html2010年10月29日閲覧。
^"Pradax (Dabigatran Etexilate) Gains Approval In Canada For Stroke Prevention In Atrial Fibrillation" Medical News Today. 28 October 2010.
^Merli G, Spyropoulos AC, Caprini JA; Spyropoulos; Caprini (August 2009). “Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations”. Ann Surg(英語版)250 (2): 219–28. doi:10.1097/SLA.0b013e3181ae6dbe. PMID 19638915.
^Connolly, SJ; Ezekowitz, MD; Yusuf, S et al. (September 2009). “Dabigatran versus warfarin in patients with atrial fibrillation” (PDF). N Engl J Med361 (12): 1139–51. doi:10.1056/NEJMoa0905561. PMID 19717844. http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905561.
^Turpie AG (January 2008). “New oral anticoagulants in atrial fibrillation”. Eur Heart J(英語版)29 (2): 155–65. doi:10.1093/eurheartj/ehm575. PMID 18096568.
^“Boehringer wins first US OK in blood-thinner race”. Thomson Reuters. (2010年10月19日). http://www.reuters.com/article/2010/10/19/boehringer-pradaxa-idUSN19165636201010192010年10月20日閲覧。
^“FDA approves Pradaxa to prevent stroke in people with atrial fibrillation”. U.S. Food and Drug Administration (FDA). (2010年10月19日). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm
^Shirley S. Wang (2010年9月20日). “New Blood-Thinner Recommended by FDA Panel”. The Wall Street Journal. http://blogs.wsj.com/health/2010/09/20/new-blood-thinner-recommended-by-fda-panel/2010年10月20日閲覧。
^“経口直接トロンビン阻害薬「プラザキサカプセル」が国内で承認”. THERAPEUTIC RESEARCH (2011年1月21日). 2015年2月28日閲覧。
^Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK; Curtis; Ellenbogen; Estes Na; Ezekowitz; Jackman; January; Lowe et al. (March 2011). “2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines”. Circulation123 (10): 1144–50. doi:10.1161/CIR.0b013e31820f14c0. PMID 21321155.
^“FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin”. 2015年2月28日閲覧。
^Cohen, D (July 2014). “Dabigatran: how the drug company withheld important analyses”. BMJ349: g4670. doi:10.1136/bmj.g4670. PMID 25055829.
^Moore TJ, Cohen MR, Mattison DR; Cohen; Mattison (July 2014). “Dabigatran, bleeding, and the regulators”. BMJ349: g4517. doi:10.1136/bmj.g4517. PMID 25056265.
外部リンク
プラザキサ 製品情報サイト
Pradaxa.com. Boehringer Ingelheim.
dabigatran.com. Boehringer Ingelheim.
Pradaxa For U.S. Health Care Professionals. Boehringer Ingelheim.
Ramiro Burr's New Blog - to go back: www.ramiroburr.com From Latin rock to reggaeton, boleros to blues,Tex-Mex to Tejano, conjunto to corridos and beyond, Ramiro Burr has it covered. If you have a new CD release, a trivia question or are looking for tour info, post a message here or e-mail Ramiro directly at: musicreporter@gmail.com Top Tejano songwriter Luis Silva dead of heart attack at 64 By Ramiro Burr on October 23, 2008 8:40 AM | Permalink | Comments (12) | TrackBacks (0) UPDATE: Luis Silva Funeral Service details released Visitation 4-9 p.m. Saturday, Rosary service 6 p.m. Saturday at Porter Loring, 1101 McCullough Ave Funeral Service 10:30 a.m. Monday St. Anthony De Padua Catholic Church, Burial Service at Chapel Hills, 7735 Gibbs Sprawl Road. Porter Loring (210) 227-8221 Related New Flash: Irma Laura Lopez: long time record promoter killed in accident NewsFlash: 9:02 a.m. (New comments below) Luis Silva , one of the most well-known ...